AHA/ACC/HFSA 2022 + ESC 2023

The Heart Failure Journey

From first suspicion through diagnosis, GDMT, monitoring, and acute exacerbation. Click any stage to expand.

Stage 1 · Presentation

Clinical Suspicion & Initial Evaluation

Patient presents with dyspnea, fatigue, orthopnea, PND, or lower extremity edema. The initial evaluation aims to confirm HF, determine etiology, and assess severity.

Click to expand guideline details ↓

AHA/ACC 2022 · Universal Definition HF requires all of: (1) Symptoms and/or signs of HF; (2) Objective evidence of cardiac structural/functional abnormality; (3) Corroboration by natriuretic peptides or objective evidence of pulmonary/systemic congestion.

ESC 2021/2023 For non-acute presentation: if BNP ≥35 pg/mL or NT-proBNP ≥125 pg/mL → proceed to echocardiography. If natriuretic peptides are normal, HF is very unlikely (NPV >98%).

Key symptoms: Dyspnea (exertional → rest), orthopnea, PND, bendopnea, fatigue, exercise intolerance, early satiety, RUQ fullness
Key signs: JVD, S3 gallop, laterally displaced PMI, hepatojugular reflux, peripheral edema, ascites, rales (often absent in chronic HF due to lymphatic adaptation)
BNP: BNP ≥100 pg/mL or NT-proBNP ≥300 pg/mL in acute setting suggests HF. NT-proBNP age-stratified: ≥450 (<50 yr), ≥900 (50–75 yr), ≥1800 (>75 yr)
BNP caveats: Falsely low in obesity (BMI >35: halved levels). Falsely elevated in AF, renal dysfunction, acute PE, sepsis. Neprilysin inhibitor (sacubitril) raises BNP but lowers NT-proBNP — use NT-proBNP for monitoring on ARNI

Clinical Pearl The Framingham criteria (2 major or 1 major + 2 minor) remain useful for clinical diagnosis but are not part of the modern universal definition. The universal definition explicitly requires objective evidence beyond symptoms alone.

Stage 2 · Workup

Diagnostic Evaluation & Phenotyping

Echocardiography is the cornerstone. Labs identify etiology and comorbidities. The goal is to classify HF phenotype (HFrEF: EF ≤40%), determine etiology, and assess hemodynamic status.

Click to expand ↓

AHA/ACC 2022 · Recommended Workup Class I: TTE with Doppler for all patients with suspected HF. CBC, CMP (Na, K, Cr, BUN, glucose), LFTs, TSH, iron studies (ferritin + TSAT), lipid panel, urinalysis, 12-lead ECG, chest X-ray. Natriuretic peptides (BNP or NT-proBNP).

Echo findings in HFrEF: LVEF ≤40% (biplane Simpson). Assess LV dimensions (LVIDd, LVIDs), wall thickness, wall motion (global vs. regional), LA volume index, RV function (TAPSE, S'), TR jet for RVSP, IVC for RAP, diastolic parameters
Etiology workup: Ischemic: coronary angiography or stress testing if CAD suspected. Non-ischemic: consider cardiac MRI (gadolinium enhancement for myocarditis, sarcoidosis, amyloid). Genetic testing if familial DCM suspected (TTN, LMNA, MYH7)
Iron deficiency: Ferritin <100 ng/mL, or ferritin 100–300 with TSAT <20% = iron deficiency. Present in 30–50% of HFrEF. Treat with IV iron regardless of anemia status CLASS IIa
Cardiac MRI: Gold standard for LV volumes/EF. Late gadolinium enhancement patterns: subendocardial (ischemic), mid-wall (DCM, myocarditis, sarcoid), subepicardial (myocarditis). T1/T2 mapping for edema, fibrosis, infiltration
Right heart catheterization: When diagnosis uncertain, pre-transplant/LVAD evaluation, or to distinguish pre- vs. post-capillary PH. Measures: RA, RV, PA pressures, PCWP, CO/CI, PVR, transpulmonary gradient
Endomyocardial biopsy: Consider in rapidly progressive HF of unknown etiology, suspected giant cell myocarditis, eosinophilic myocarditis, or restrictive cardiomyopathy when non-invasive workup inconclusive

ESC 2023 Focused Update Cardiac MRI recommended when echo is inconclusive or for tissue characterization in non-ischemic cardiomyopathy. CT coronary angiography is an acceptable alternative to invasive angiography for excluding CAD in low-intermediate probability patients.

Stage 3 · Pathophysiology & Echo

Understanding the Failing Heart: Why Everything Changes

Before treating, understand the hemodynamic cascade. HFrEF is a syndrome of progressive ventricular remodeling driven by neurohormonal activation. Every echo parameter reflects a specific pathophysiologic mechanism — understanding the why behind each number transforms echo from pattern recognition into clinical reasoning.

Click to expand pathophysiology ↓

Core Concept · The Remodeling Spiral LaPlace’s Law (T = P × r / 2h): Wall stress equals pressure times radius divided by twice the wall thickness. When myocyte loss causes chamber dilation (↑r) and wall thinning (↓h), wall stress increases exponentially. This triggers further hypertrophy, fibrosis, and dilation — a self-perpetuating cycle. Every echo measurement in HFrEF maps back to this equation.

Neurohormonal Activation: The Triple Axis: RAAS: Reduced CO → renal hypoperfusion → renin release → angiotensin II (vasoconstriction, aldosterone secretion, cardiac fibrosis, myocyte hypertrophy) → aldosterone (Na/H₂O retention, K wasting, myocardial fibrosis). This is why ACEi/ARB/ARNI + MRA are foundational.

Sympathetic nervous system: Baroreceptor unloading → catecholamine surge → chronotropy, inotropy, vasoconstriction. Short-term: maintains CO. Long-term: beta-receptor downregulation, direct myocyte toxicity (calcium overload → apoptosis), arrhythmogenesis. This is why beta-blockers reduce mortality despite being “negative inotropes.”

ADH/Vasopressin: Non-osmotic release from reduced effective circulating volume → free water retention → hyponatremia (Na <135 is one of the strongest predictors of mortality in HF). Serum sodium is a free prognostic biomarker.
Natriuretic Peptide System: ANP (atrial stretch) and BNP (ventricular wall stress) oppose RAAS: vasodilation, natriuresis, suppress aldosterone and SNS. But in HF, the system is overwhelmed — neprilysin (which degrades natriuretic peptides) becomes a therapeutic target. This is the rationale for sacubitril/valsartan (ARNI): inhibiting neprilysin boosts endogenous NPs while blocking AT-II receptors.
Frank-Starling Mechanism: Early compensation: increased preload stretches sarcomeres → increased force generation → maintained CO on the steep portion of the curve. As remodeling progresses, the curve flattens and shifts right — increased preload no longer increases output but instead causes pulmonary congestion. The patient transitions from “compensated” to “decompensated” HF. On echo, this manifests as elevated filling pressures (E/e′ >14) with reduced CO (low LVOT VTI).
The MR – Dilation Vicious Cycle: LV dilation → mitral annular dilation + papillary muscle displacement → leaflet malcoaptation → functional MR → volume overload on an already failing LV → more dilation → more MR. This is why secondary MR severity tracks disease progression and why effective GDMT reduces MR (reverse remodeling shrinks the annulus). On echo: MR PISA, vena contracta, and regurgitant volume increase as the LV dilates.

Attending-Level Concept The entire basis of GDMT in HFrEF is neurohormonal blockade. ACEi/ARNI blocks RAAS. Beta-blockers block SNS. MRA blocks aldosterone. SGLT2i adds osmotic diuresis, reduces preload, and has direct cardioprotective effects (mechanisms still being elucidated — likely includes improved myocardial energetics, reduced inflammation, and autophagy regulation). Each drug targets a different limb of the same pathologic cascade.

📊 Echo Deep Dive
LVEF (Biplane Simpson): What: End-diastolic volume minus end-systolic volume, divided by end-diastolic volume. Traced from A4C + A2C views.
Why it matters: The primary classifier of HF type (≤40% = HFrEF). Every major trial uses EF for enrollment.
Why it changes: In HFrEF, reduced myocyte contractility → increased ESV while EDV also increases (dilation) → net decrease in EF.
Limitations: Load-dependent (afterload reduction alone can improve EF by 5–10%). Inter-observer variability ±5–10%. Foreshortened A4C overestimates EF. 3D echo and CMR are more accurate but less available.
Clinical pearl: Never make a major decision (ICD implant, transplant listing) on a single EF measurement. Confirm with repeat imaging or alternative modality. An EF of 36% has a 95% CI of roughly 26–46%.
E/A Ratio — The Diastolic Fingerprint: What it measures: E = peak velocity of early passive filling across the mitral valve. A = peak velocity of late filling from atrial contraction. Measured by pulsed-wave Doppler at the mitral leaflet tips.
The physiology: E is driven by the LA-to-LV pressure gradient at the moment of mitral valve opening. This depends on two factors: (1) how fast the LV relaxes and “sucks” blood in (active relaxation/recoil), and (2) how high the LA pressure is. A is driven purely by atrial contractile force.
Evolution in HFrEF:
• Grade I (Impaired relaxation): E/A <0.8. Relaxation slows → less LV suction → lower E. LA pressure still normal, so A becomes dominant. DT >200 ms. The patient may be asymptomatic.
• Grade II (Pseudonormal): E/A 0.8–2.0. LA pressure rises enough to “push” blood across despite poor relaxation → E normalizes. The trap: looks like a normal pattern. Unmask with Valsalva (reduces preload → drops E/A by ≥0.5) or with tissue Doppler (e′ remains low).
• Grade III (Restrictive): E/A >2.0, DT <150 ms. LA pressure is so high that early filling is very rapid and the pressure gradient equalizes quickly. This is the worst pattern — associated with highest mortality. Grade IIIa reverses with Valsalva; Grade IIIb (fixed) does not.
E/e′ Ratio — The Filling Pressure Estimator: The single most important concept in diastology.
E: Mitral inflow velocity — reflects the LA–LV pressure gradient (influenced by BOTH relaxation AND filling pressure).
e′: Mitral annular velocity from tissue Doppler — reflects intrinsic myocardial relaxation velocity, relatively independent of loading conditions.
The ratio: E is contaminated by two variables (relaxation + pressure). e′ isolates relaxation. Dividing E by e′ mathematically “cancels out” the relaxation component, leaving you with an estimate of filling pressure alone.

Think of it this way: E = what the blood does. e′ = what the muscle does. The ratio = how much of the blood movement is being driven by pressure (not relaxation).

Cutoffs: Average (septal + lateral / 2) E/e′ <8 = normal LAP. 8–14 = indeterminate. >14 = elevated LAP (≈ PCWP >15 mmHg). Septal E/e′ >15 or lateral E/e′ >13 also indicate elevated pressures.
In HFrEF: Typically elevated (>14–20+). Correlates with PCWP. Use it to assess filling pressure non-invasively, guide diuresis, and prognosticate.
Pitfalls: E/e′ is unreliable in: severe mitral annular calcification (restricts annular motion → falsely low e′), mitral stenosis, constrictive pericarditis (e′ can be preserved or elevated = annulus reversus), and immediately post-cardiac surgery.
Deceleration Time (DT): What: Time from E-wave peak to baseline. Reflects how quickly LA and LV pressures equalize after mitral valve opening.
Why it changes: Long DT (>240 ms) = slow equalization = good LV compliance but impaired relaxation (LA pressure not very elevated). Short DT (<150 ms) = rapid equalization = either a very stiff LV or very high LA pressure (the gradient drops fast because pressures equalize quickly in a non-compliant chamber).
In HFrEF: DT <150 ms (restrictive filling) is an independent predictor of cardiac death. It indicates the LV is so stiff or LA pressure so high that filling completes in a fraction of the normal time.
GLS — Global Longitudinal Strain: What: Speckle-tracking echocardiography measures myocardial deformation. GLS specifically measures longitudinal shortening (base to apex) as a percentage. Normal ≤ −20% (more negative = more shortening = better function).
Why it’s more sensitive than EF: The LV contracts in three directions: longitudinal, circumferential, and radial. Longitudinal fibers run in the subendocardium — the layer most vulnerable to ischemia, fibrosis, and pressure overload. GLS detects subendocardial dysfunction BEFORE circumferential/radial compensation fails (which is when EF drops).
In HFrEF: GLS is severely reduced (> −10% in advanced disease). GLS predicts outcomes independently of and better than EF. A GLS of −12% with an EF of 38% has worse prognosis than a GLS of −16% with the same EF.
Vendor variability: Normal ranges differ by vendor (GE vs. Philips vs. Siemens). Always compare to the same vendor’s reference range. The ASE recommends vendor-specific normative data.
LAVI — Left Atrial Volume Index: What: LA volume (biplane Simpson from A4C + A2C, measured at end-systole when LA is largest) divided by BSA.
Why it matters: LA size reflects chronic filling pressure exposure. A dilated LA (>34 mL/m²) means filling pressures have been elevated for weeks to months. It is the “HbA1c of diastolic function” — a time-integrated measure, not a snapshot.
In HFrEF: Progressively dilates with disease severity. LAVI >40 mL/m² independently predicts hospitalization and death. Also predicts AF development (stretched LA → electrical remodeling → AF → further hemodynamic deterioration).
TAPSE — RV Systolic Function: What: M-mode measurement of tricuspid annular excursion toward the apex during systole. Measures RV longitudinal shortening. Normal ≥17 mm.
Why it matters in HFrEF: RV failure is the single strongest predictor of death in HFrEF. The RV fails from: (1) elevated LV filling pressures → pulmonary venous HTN → pulmonary arterial HTN → RV pressure overload; (2) ventricular interdependence (shared septum, shared pericardial space); (3) RV coronary hypoperfusion (RV perfusion depends on the aortic-to-RV pressure gradient, which narrows in RV HTN).
Complementary measures: S′ (TDI at TV annulus, normal ≥9.5 cm/s), FAC (RV fractional area change, normal ≥35%), RV free wall strain (normal > −20%). No single measure captures the complex RV geometry — use at least two.
dP/dt — Contractility Estimate: What: Rate of LV pressure rise in early systole. Derived from the MR continuous-wave Doppler signal: time from 1 m/s to 3 m/s. dP/dt = 32 mmHg / (time in seconds).
Why: During isovolumetric contraction, LV pressure rises. The rate of rise reflects intrinsic contractility, independent of afterload (aortic valve is closed) and relatively independent of preload.
Normal: >1200 mmHg/s. <800 = severely impaired contractility. Useful for serial monitoring — improving dP/dt on GDMT is a good sign. Only measurable when MR is present.
Tei Index (MPI): What: Myocardial Performance Index = (IVCT + IVRT) / ET. Combines isovolumetric contraction time, isovolumetric relaxation time, and ejection time into a single ratio that reflects both systolic AND diastolic function.
Why: A normal heart spends most of its cycle in ejection (productive work), with short isovolumetric periods (overhead). In HFrEF, ejection time shortens (weak contraction) and isovolumetric times lengthen (slow pressure generation and relaxation) → Tei index rises.
Normal: <0.40 (pulsed Doppler) or <0.30 (TDI). Elevated in both HFrEF and HFpEF. Prognostic value independent of EF.
Cardiac Output (LVOT VTI Method): What: CO = SV × HR. SV = LVOT VTI × LVOT area. LVOT diameter measured in PLAX (area = π × (d/2)²). VTI measured by pulsed-wave Doppler in A5C, sample volume in the LVOT just proximal to the aortic valve.
Normal LVOT VTI: 18–22 cm. <18 cm = low stroke volume. Stroke Volume Index (SVi) = SV/BSA. <35 mL/m² = low-flow state.
In HFrEF: Reduced LVOT VTI is the direct hemodynamic consequence of reduced contractility. Useful for: (1) identifying low-flow low-gradient aortic stenosis vs. pseudo-stenosis, (2) monitoring response to inotropes in cardiogenic shock, (3) calculating MR regurgitant volume (total SV − forward SV).

Putting It All Together · The HFrEF Echo Report A complete HFrEF echo assessment integrates: LV size (LVIDd/LVIDs — is it dilated?), Wall thickness (thin in DCM, thick if prior HTN), EF (biplane Simpson + visual), GLS (subclinical trajectory), Diastolic grade (E/A + E/e′ + DT + LAVI + TR vel → ASE algorithm), Filling pressures (E/e′ + LAVI + TR vel → elevated vs. normal), MR severity (mechanism + quantitation), RV function (TAPSE + S′ + FAC), RVSP (from TR jet), IVC/RAP, and Contractility (dP/dt if MR present). Together, these parameters tell you not just that the heart is failing, but how — and guide every therapeutic decision.

Stage 4 · Foundation Therapy

The Four Pillars of GDMT

All four drug classes should be initiated as soon as possible, ideally within the first hospitalization. Simultaneous or rapid-sequence initiation is preferred over the traditional slow up-titration approach. Each pillar independently reduces mortality.

Click to expand ↓

Pillar 1

ARNI / ACEi / ARB

Neurohormonal blockade

PARADIGM-HF, CONSENSUS, SOLVD

Pillar 2

Beta-Blocker

Sympathetic blockade

MERIT-HF, CIBIS-II, COPERNICUS

Pillar 3

MRA

Aldosterone antagonism

RALES, EMPHASIS-HF

Pillar 4

SGLT2 Inhibitor

Cardiorenal protection

DAPA-HF, EMPEROR-Reduced

AHA/ACC 2022 · Medication Details ARNI (sacubitril/valsartan): Preferred over ACEi/ARB. Start 24/26 mg BID if ACEi-naive or low BP; target 97/103 mg BID. 36-hour ACEi washout required. PARADIGM-HF: 20% mortality reduction vs. enalapril. CLASS I

ACEi: If ARNI not tolerated/available. Enalapril target 10–20 mg BID, lisinopril 20–40 mg daily, ramipril 5 mg BID. CLASS I

ARB: If ACEi intolerant (cough). Valsartan 160 mg BID, losartan 50–150 mg daily, candesartan 32 mg daily. CLASS I

Beta-blocker: Only evidence-based BBs: carvedilol (25 mg BID, or 50 mg BID if >85 kg), metoprolol succinate (target 200 mg daily), bisoprolol (target 10 mg daily). Start low, uptitrate every 2 weeks. Do NOT initiate in acute decompensation — start once euvolemic. CLASS I

MRA: Spironolactone 25–50 mg daily or eplerenone 25–50 mg daily. RALES: 30% mortality reduction. Monitor K+ and Cr closely — hold if K >5.5 or eGFR <30. CLASS I

SGLT2i: Dapagliflozin 10 mg or empagliflozin 10 mg daily. DAPA-HF/EMPEROR-Reduced: 25% reduction in CV death + HF hospitalization. Benefits occur regardless of diabetes status. Can start during hospitalization. Few side effects; GU mycotic infections most common. CLASS I

Practical Tips Rapid-sequence initiation: Start all 4 pillars within 1–2 weeks rather than sequential add-on over months. The STRONG-HF trial showed that rapid up-titration (within 2 weeks of discharge) reduced 180-day death or HF readmission by 34%.

BP permissive: Accept SBP down to 90–100 mmHg if asymptomatic. Symptomatic hypotension is the limit, not a number.

Creatinine bump: Up to 30% Cr rise with RAAS inhibition is acceptable and expected. Do not reflexively stop medications for mild Cr elevation.

Stage 5 · Additional Therapies

Beyond the Four Pillars

Diuretics for congestion, hydralazine/nitrates for specific populations, ivabradine for persistent tachycardia, IV iron for iron deficiency, and anticoagulation considerations.

Click to expand ↓

Loop diuretics: Furosemide, bumetanide, or torsemide for volume management. NOT mortality-reducing — use lowest dose for euvolemia. Torsemide may have advantages (longer half-life, anti-fibrotic properties, better bioavailability). CLASS I for congestion relief
Hydralazine/Isosorbide dinitrate: A-HeFT trial: 43% mortality reduction in self-identified Black patients with NYHA III–IV HFrEF on standard therapy. Fixed-dose combination: hydralazine 75 mg + ISDN 40 mg TID. CLASS I for Black patients; CLASS IIb for RAAS-intolerant patients of other races
Ivabradine: SHIFT trial. For sinus rhythm with HR ≥70 bpm despite maximally tolerated BB. Selectively inhibits I(f) current in SA node. CLASS IIa
Vericiguat: VICTORIA trial. Soluble guanylate cyclase stimulator. For worsening HF (recent hospitalization/IV diuretic). Modest benefit: 10% relative reduction in CV death + HF hosp. CLASS IIb
IV iron: Ferric carboxymaltose or iron sucrose if ferritin <100 or ferritin 100–300 + TSAT <20%. AFFIRM-AHF, IRONMAN trials. Improves symptoms, functional capacity, and quality of life. Reduces HF hospitalizations. CLASS IIa
Digoxin: DIG trial: reduces hospitalizations but no mortality benefit. Use for rate control in AF or persistent symptoms despite GDMT. Target trough 0.5–0.9 ng/mL. CLASS IIb
Anticoagulation: Routine AC not recommended for HFrEF in sinus rhythm (COMMANDER-HF, WARCEF neutral). Indicated for: AF, LV thrombus, prior embolism, mechanical valve

ESC 2023 Focused Update Finerenone (non-steroidal MRA) may have a future role in HFrEF with CKD and diabetes based on FIDELIO-DKD/FIGARO-DKD, but not yet recommended for HFrEF specifically. GLP-1 receptor agonists (semaglutide) show promise for HF with obesity phenotype — STEP-HFpEF was positive; HFrEF trials ongoing.

Stage 6 · Device Therapy

ICD, CRT, and Cardiac Monitoring

After at least 3 months of optimized GDMT, reassess EF. Device therapy for appropriate patients reduces sudden cardiac death (ICD) and improves remodeling (CRT).

Click to expand ↓

AHA/ACC 2022 · ICD Primary prevention ICD: LVEF ≤35% despite ≥3 months of optimal GDMT, NYHA II–III, expected survival >1 year. CLASS I
Ischemic etiology: EF ≤30% regardless of NYHA class. Must be ≥40 days post-MI and ≥90 days post-revascularization. CLASS I
Non-ischemic: EF ≤35%, NYHA II–III. DANISH trial showed trend but not significant for all-cause mortality; however, subgroup <68 yr benefited. CLASS I per AHA; ESC is more nuanced
Do NOT implant: Within 40 days of MI, within 90 days of revascularization, NYHA IV not candidate for CRT/LVAD/transplant, expected survival <1 year, reversible cause

AHA/ACC 2022 · CRT CRT-D (strongest indication): EF ≤35% + LBBB + QRS ≥150 ms + NYHA II–III (ambulatory IV) on GDMT + sinus rhythm. CLASS I
CRT-D (moderate): EF ≤35% + LBBB + QRS 120–149 ms + NYHA II–III/IV. CLASS IIa
CRT-D (weaker): EF ≤35% + non-LBBB + QRS ≥150 ms. CLASS IIa
CRT in AF: Same EF/QRS criteria but must achieve >99% biventricular pacing (often requires AV node ablation). CLASS IIa
CRT response: ~70% respond; super-responders (≥15% LVESV reduction) may normalize EF. Predictors: female, LBBB, non-ischemic, wider QRS

Wearable defibrillator (LifeVest): Bridge therapy when ICD indicated but criteria not yet met (within 40-day MI window, within 90 days post-revasc, new HF diagnosis awaiting GDMT optimization). VEST trial: trend to benefit, not statistically significant. CLASS IIb
Cardiac contractility modulation (CCM): Optimizer device: non-excitatory electrical signals during absolute refractory period. For NYHA III, EF 25–45%, narrow QRS (not CRT candidate). FIX-HF-5C trial positive. CLASS IIb
Remote monitoring: CardioMEMS (PA pressure sensor): CHAMPION trial showed 37% reduction in HF hospitalizations. For NYHA III with prior HF hospitalization. CLASS IIa

Stage 7 · Ongoing Monitoring

Serial Assessment & Optimization

GDMT up-titration to target doses, serial biomarkers, functional assessment, and surveillance for disease progression. The goal is optimal dosing, not just drug initiation.

Click to expand ↓

GDMT up-titration: Double dose every 1–2 weeks as tolerated. Target: ARNI 97/103 BID, carvedilol 25 mg BID (50 if >85 kg), metoprolol succinate 200 mg daily, spironolactone 25–50 mg, SGLT2i already at full dose. Patients receiving ≥50% target doses of all 4 pillars have significantly better outcomes than those on subtherapeutic doses
Repeat echo: Repeat TTE at 3–6 months after initiation/optimization of GDMT. If EF improves to >40%, reclassify as HF with improved EF (HFimpEF) but continue all GDMT — TRED-HF showed withdrawal leads to relapse in 44% within 6 months
NT-proBNP trend: Serial monitoring guides therapy. GUIDE-IT trial (biomarker-guided) was neutral for composite endpoint, but ≥30% reduction from baseline associated with better outcomes. Use NT-proBNP (not BNP) if on sacubitril/valsartan
Lab monitoring: BMP (K, Cr, eGFR) within 1–2 weeks of RAAS changes, then every 3–6 months. Yearly: TSH, iron studies, CBC, LFTs. K >5.5: reduce MRA. Cr rise >30%: evaluate for over-diuresis, renal artery stenosis
Functional status: NYHA class, 6-minute walk test (<300 m = poor prognosis), KCCQ (Kansas City Cardiomyopathy Questionnaire, 23-item PRO). ≥5-point KCCQ improvement = clinically meaningful
HF with improved EF: If EF recovers >40%, patient is HFimpEF — NOT cured. Continue all 4 pillars indefinitely. If EF >35%: ICD may be re-evaluated. If EF normalizes (>50%): still maintain GDMT; reassess annually

Common Pitfall The #1 modifiable predictor of poor outcomes in HFrEF is failure to up-titrate GDMT to target doses. In CHAMP-HF registry, <1% of eligible patients were on target doses of all 3 original pillars. Barriers include therapeutic inertia, hypotension fears, and renal function anxiety. Accept SBP 90–100 if asymptomatic. Accept Cr bumps up to 30%.

Stage 8 · Acute Decompensation

Hospital Management of ADHF

Acute decompensated HF (ADHF) requires IV diuretics, hemodynamic stabilization, and rapid optimization of GDMT before discharge. In-hospital mortality is 4–7%; 90-day readmission is 25–30%.

Click to expand ↓

AHA/ACC 2022 · Acute Management IV diuretics: Furosemide IV bolus (dose ≥ home oral dose) or continuous infusion. Target ≥3–5 L net negative in first 48 hours. DOSE trial: high-dose strategy (2.5× home dose) had greater diuresis with transient Cr rise but similar outcomes. CLASS I

Diuretic resistance: Sequential nephron blockade — add metolazone 2.5–5 mg or chlorothiazide 250–500 mg IV 30 min before loop diuretic. Monitor Na and K closely (risk of profound electrolyte depletion). Acetazolamide 500 mg IV daily (ADVOR trial: greater decongestion at 3 days). CLASS IIa

Warm & wet (most common): Congested, adequate perfusion. Treatment: IV diuretics, continue oral GDMT if BP allows. Vasodilators (nitroglycerin drip) if SBP >110. Decongestion is the primary goal
Cold & wet: Congested + hypoperfused (low CO). SBP <90, cool extremities, narrow pulse pressure, declining UOP, rising lactate. Treatment: inotropes (dobutamine, milrinone) + cautious diuresis. Consider PA catheter. If refractory: mechanical support (Impella, IABP)
Cold & dry: Low CO without congestion. Rare. Cautious IV fluids to optimize preload, then inotropes if needed. Often medication-related (over-diuresis, BB excess)
Inotropes: Dobutamine: beta-1 agonist, increases CO, may increase HR and arrhythmia risk. Milrinone: PDE3 inhibitor, inotropy + vasodilation, preferred in PH/RV failure. Avoid prolonged use (increased mortality). Bridge to recovery, decision, or destination therapy only
Vasopressors: Norepinephrine preferred over dopamine for cardiogenic shock (SOAP II). Vasopressin for refractory vasodilatory shock. Phenylephrine contraindicated (pure afterload without inotropy)
Decongestion markers: Daily weights (target ≥1 kg/day), strict I/O, spot urine Na (goal >50 mEq/L after diuretic = adequate response), hemoconcentration (rising Hgb/Hct), improving JVP, resolving edema

ESC 2023 · Pre-Discharge Checklist Before discharge: (1) Initiate/optimize all 4 GDMT pillars (start SGLT2i in-hospital); (2) Switch IV to oral diuretics ≥24 hr before discharge; (3) Schedule follow-up within 1–2 weeks; (4) Patient education on daily weights, sodium restriction, symptom recognition; (5) Consider CardioMEMS or remote monitoring; (6) Medication reconciliation; (7) Ensure LVEF documented — if ≤35% after ≥3 months GDMT, refer for ICD evaluation.

Clinical Pearl The vulnerable period is the first 30 days post-discharge. STRONG-HF showed that rapid GDMT intensification with close follow-up (within 1–2 weeks) during this window dramatically reduces readmissions and death. The transition of care is as important as the hospital stay.

Stage 9 · Advanced Heart Failure

Stage D — LVAD, Transplant, & Palliative Care

For patients with persistent severe symptoms despite optimal GDMT and device therapy. INTERMACS profiles guide urgency. Referral to advanced HF center should occur before clinical deterioration becomes irreversible.

Click to expand ↓

AHA/ACC 2022 · Advanced HF Criteria Refer to advanced HF specialist if: (1) NYHA IIIb–IV despite optimal GDMT; (2) ≥2 HF hospitalizations in 12 months; (3) Escalating diuretic requirements; (4) Need for inotropes; (5) Peak VO2 <14 mL/kg/min (or <12 if on BB); (6) Cardiac cachexia; (7) Persistent hyponatremia (Na <134); (8) Refractory ventricular arrhythmias. CLASS I

LVAD (durable): HeartMate 3: fully magnetically levitated centrifugal pump. MOMENTUM 3 trial: 77% survival at 2 years. Bridge to transplant or destination therapy (DT). Complications: GI bleeding, driveline infection, pump thrombosis (rare with HM3), stroke, RV failure post-implant
Heart transplant: Gold standard for appropriate candidates. Median survival >12.5 years. Allocation by medical urgency (Status 1–6 system since 2018). Contraindications: irreversible PH (PVR >5 WU not responsive to vasodilators), active malignancy, systemic infection, severe renal/hepatic dysfunction, psychosocial barriers
Palliative care: Should be integrated early, not just at end of life. Goals of care discussion, symptom management (opioids for refractory dyspnea), psychosocial support. Hospice when prognosis <6 months and patient elects comfort-focused care. ICD deactivation discussion at appropriate time
INTERMACS profiles: 1 = critical cardiogenic shock (crash and burn); 2 = progressive decline on inotropes (sliding on inotropes); 3 = stable on inotropes (dependent stability); 4 = resting symptoms (frequent flyer); 5 = exertion intolerant; 6 = walking wounded; 7 = advanced NYHA III. Profiles 1–3: urgent MCS evaluation. Profiles 4–7: elective transplant/LVAD evaluation

Stage 10 · Prognosis & Outcomes

Risk Stratification & Long-Term Outlook

With optimized GDMT, 5-year survival for HFrEF has improved from ~25% (pre-GDMT era) to ~60–70%. Risk scores integrate echo, biomarkers, and functional data to guide decisions.

Click to expand ↓

MAGGIC score: Meta-Analysis Global Group in Chronic HF. Validated in 39,372 patients. Variables: age, EF, NYHA, Cr, diabetes, BB use, SBP, BMI, time since diagnosis. Online calculator provides 1- and 3-year mortality estimates
Seattle HF Model: Most comprehensive. Includes medications, devices, labs, echo, exercise data. Predicts 1-, 2-, and 3-year survival. Useful for transplant timing discussions
Key prognostic markers: Echo: LVEF, restrictive filling (DT <150 ms worst), RV dysfunction (TAPSE <17), RVSP >60 mmHg. Labs: NT-proBNP, hs-troponin, Na <134, rising Cr, sST2, galectin-3. Functional: Peak VO2 <14, VE/VCO2 slope >35, 6MWT <300 m
HF with improved EF: Best prognosis of all HF phenotypes when maintained on GDMT. Annual mortality 2–5% (vs. 10–15% for persistent HFrEF). Must continue all medications — TRED-HF: 44% relapse within 6 months of withdrawal

The Big Picture Modern GDMT has transformed HFrEF from a rapidly fatal disease to a chronic manageable condition for many. The four pillars together reduce mortality by ~50–60% compared to no GDMT. The key challenges remain: therapeutic inertia (failure to titrate), health disparities in access to care, and late referral to advanced HF services.

Stage 1 · Presentation

The Diagnostic Challenge

HFpEF is the most commonly missed HF diagnosis. Patients present with exertional dyspnea, fatigue, and fluid retention but have a normal or near-normal EF. The diagnosis requires integrating symptoms, echo, and natriuretic peptides — and often exercise testing.

Click to expand ↓

Typical patient: Older (60+), female, obese, hypertensive, diabetic, with AF. Presents with dyspnea on exertion, exercise intolerance, and peripheral edema. Often diagnosed as "deconditioning" or "COPD"
BNP in HFpEF: May be only mildly elevated or even normal at rest (especially in obesity). NT-proBNP ≥125 pg/mL supports diagnosis. Obesity reduces BNP levels by ~50% — a BNP of 50 in a BMI 40 patient is like a BNP of 100 in a normal-weight patient
Why it's missed: Normal EF on echo → "heart is fine." But EF measures radial function; longitudinal function (GLS, e') is abnormal in HFpEF. Resting echo may be normal — filling pressures may only rise with exercise

AHA/ACC 2022 · Diagnosis HFpEF diagnosis requires: (1) Signs/symptoms of HF; (2) EF ≥50%; (3) Evidence of structural heart disease (LVH, LA enlargement) AND/OR diastolic dysfunction AND/OR elevated natriuretic peptides AND/OR elevated filling pressures (invasive or non-invasive). If uncertain at rest, exercise testing (diastolic stress echo or invasive exercise hemodynamics) can confirm.

Stage 2 · Diagnostic Algorithms

H2FPEF, HFA-PEFF & ASE Diastolic Grading

Scoring systems integrate multiple parameters to establish the diagnosis with confidence, particularly when resting echo is indeterminate.

Click to expand ↓

H2FPEF Score (Mayo Clinic) Heavy: BMI >30 (+2 pts)
2: ≥2 antihypertensives (+1 pt)
F: AF (+3 pts)
P: Pulmonary artery systolic pressure >35 mmHg on echo (+1 pt)
E: E/e' >9 (+1 pt)
F: EF >60% (+1 pt, paradoxically — super-normal EF suggests stiff ventricle)
Score 0–9. ≥6: high probability (>90%). 2–5: intermediate (exercise testing). ≤1: low probability.

HFA-PEFF Algorithm (ESC) Step 1: Clinical suspicion (symptoms + risk factors + echo screening).
Step 2: Detailed echo — functional (E/e', GLS, TR vel) and morphological (LAVI, LV mass, LV wall thickness) domains. Major criteria score 2, minor score 1. ≥5 total = HFpEF. 2–4 = indeterminate → Step 3.
Step 3: Diastolic stress test (exercise E/e' >14 or exercise PCWP >25 mmHg via RHC).
Step 4: Etiology workup (phenotyping for specific treatment).

ASE 4 variables: (1) Average E/e' >14; (2) Septal e' <7 or lateral e' <10; (3) LAVI >34 mL/m²; (4) TR vel >2.8 m/s. ≥3/4 = Grade II diastolic dysfunction (elevated filling pressures)
Exercise echo protocol: Supine bicycle at 25W increments. Measure at each stage: E, e', TR velocity. Diagnostic cutoffs: exercise E/e' >14, exercise TR Vmax >3.4 m/s, exercise PASP >60 mmHg. Unmasks ~30% of patients with normal resting parameters
Invasive confirmation: Gold standard: PCWP >15 mmHg at rest or >25 mmHg with exercise (supine, 20W increments). Reserved for indeterminate non-invasive testing

Stage 3 · Pathophysiology & Echo

The Stiff Heart: Why Relaxation Fails

HFpEF is not simply “diastolic dysfunction.” It is a systemic syndrome where myocardial, vascular, and extracardiac derangements converge. The echo findings are the downstream manifestations of titin biology, microvascular inflammation, and impaired ventricular-arterial coupling.

Click to expand pathophysiology ↓

Core Concept · The Diastolic Cascade Normal diastole has four phases: (1) Isovolumetric relaxation — active, energy-consuming process (calcium reuptake into SR via SERCA2a, cross-bridge detachment); (2) Early filling — LV actively “sucks” blood from LA (ventricular recoil creates negative pressure gradient); (3) Diastasis — LA and LV pressures equilibrate, flow pauses; (4) Atrial contraction — LA boost pushes remaining blood into LV. In HFpEF, phases 1 and 2 are impaired first, then LV compliance decreases, and eventually all four phases are deranged.

Myocardial Mechanisms: Titin: The giant sarcomeric protein that acts as a molecular spring, determining passive myocardial stiffness. In HFpEF, the stiff N2B isoform replaces the compliant N2BA isoform. Additionally, hypophosphorylation of titin (from reduced PKG activity due to low NO/cGMP signaling) further increases stiffness. This is why the LV doesn’t fill properly — the spring is too tight.

Cardiomyocyte hypertrophy: Concentric hypertrophy (sarcomeres added in parallel) → increased wall thickness → reduced cavity compliance. Unlike HFrEF (eccentric, sarcomeres in series → elongation), HFpEF keeps wall thickness but increases stiffness.

Interstitial fibrosis: Excess collagen deposition between myocytes. Both perivascular and interstitial fibrosis contribute. Quantifiable by CMR (elevated T1, elevated ECV). Correlates with E/e′ and diastolic dysfunction severity.

Coronary microvascular dysfunction: The unifying hypothesis for HFpEF. Systemic inflammation (obesity, diabetes, metabolic syndrome) → endothelial dysfunction → reduced NO bioavailability → reduced sGC/cGMP/PKG signaling → (1) impaired titin phosphorylation (stiffness), (2) impaired myocyte relaxation (calcium handling), (3) perivascular fibrosis. This is why comorbidities DRIVE HFpEF.
Hemodynamic Consequences: At rest: Impaired relaxation → reduced LV suction → reduced early filling → increased reliance on atrial contraction. Filling pressures may be normal or only mildly elevated. Resting echo can be “normal.”

With exercise: HR increases → diastolic filling time shortens drastically. A stiff, slow-relaxing LV cannot fill in the shortened time → filling pressures rise acutely → pulmonary congestion → dyspnea. This is why 30% of HFpEF patients have normal resting hemodynamics but abnormal exercise hemodynamics — and why exercise echo/RHC is critical for diagnosis.

LA remodeling: Chronically elevated LV filling pressures transmit to the LA → LA dilation → atrial fibrillation → loss of atrial contribution to filling (loss of A wave) → further hemodynamic deterioration. AF in HFpEF is both a consequence and an accelerator.
Ventricular-Arterial Coupling: In HFpEF, both the ventricle (stiff LV) AND the arteries (stiff, non-compliant vasculature from age, HTN, diabetes) are stiff. Ventricular elastance (Ees) and arterial elastance (Ea) are both elevated, and the Ea/Ees ratio may be preserved, but the system is operating at much higher pressures. Small changes in volume (e.g., a salty meal, missed diuretic dose) cause dramatic pressure swings — this is why HFpEF patients “flash” in and out of pulmonary edema so rapidly.

Attending-Level Concept The reason we have no disease-modifying therapy as effective as GDMT in HFrEF is that HFpEF is not one disease. It is a clinical syndrome with multiple distinct pathobiologies: obesity/metabolic HFpEF, aging/fibrotic HFpEF, AF-predominant HFpEF, PH-predominant HFpEF, and specific etiologies (amyloid, HCM, constrictive). SGLT2 inhibitors (EMPEROR-Preserved, DELIVER) are the first drugs to show consistent benefit across HFpEF phenotypes — possibly because they address volume, inflammation, and energetics simultaneously.

📊 Echo Deep Dive
e′ (Tissue Doppler) — The Signature Finding: What: Early diastolic velocity of the mitral annulus, measured by pulsed-wave tissue Doppler at the septal and lateral annulus in the A4C view.
What it reflects: The speed of active LV relaxation. When the LV relaxes, the annulus moves away from the apex. Faster movement = better relaxation = higher e′.
Why it changes in HFpEF: Impaired SERCA2a function → slow calcium reuptake → slow cross-bridge detachment → slow relaxation → low e′. Also: increased myocardial stiffness (titin, fibrosis) resists annular movement.
Normal: Septal e′ ≥10 cm/s, lateral e′ ≥14 cm/s (young adults; decreases with age). Septal e′ <7 or lateral e′ <10 = abnormal.
Key insight: e′ is the earliest echo abnormality in diastolic dysfunction — it drops before E/A ratio changes, before LAVI enlarges, before symptoms develop. If you only measure one diastolic parameter, measure e′.
Pitfall: e′ is not purely load-independent. In very high filling pressures, e′ can be “pseudonormalized” (rarely). Also affected by: mitral annular calcification (artificially low), constrictive pericarditis (paradoxically high — annulus reversus).
E/e′ in HFpEF: Resting vs. Exercise: At rest: Average E/e′ may be <14 in early HFpEF. This is the “normal resting echo” trap. The patient has exertional symptoms but the echo looks fine.
With exercise: E/e′ rises to >14 during supine bicycle ergometry. This confirms exercise-induced elevation of filling pressures. The ASE recommends reporting both rest and peak exercise E/e′.
Mechanism: At rest, compensatory mechanisms maintain near-normal filling pressures. With exercise, tachycardia shortens diastole, the stiff LV cannot accommodate rapid filling, and LA pressure rises — E increases (higher driving pressure) but e′ remains low (relaxation doesn’t improve with exercise) → E/e′ rises.
LA Reservoir Strain — The Emerging Gold Standard: What: Speckle-tracking measurement of LA deformation during ventricular systole (when the LA stretches to accommodate pulmonary venous return). Normal >35%.
Why it matters: LA strain reflects intrinsic LA function AND LV filling pressures. It is abnormal BEFORE LAVI enlarges and BEFORE E/e′ is clearly elevated. Some experts consider it the most sensitive non-invasive marker of diastolic dysfunction.
Cutoffs: <24% predicts elevated PCWP (>15 mmHg). <16% strongly predicts AF recurrence post-ablation. May replace LAVI in future ASE algorithms.
Limitation: Requires adequate image quality, not yet universally standardized across vendors.
GLS in HFpEF: Normal EF, Abnormal Strain: The key paradox: EF is ≥50% (that’s the definition). But GLS is usually mildly reduced (−16% to −18%).
Why: EF is a volumetric measure dominated by circumferential and radial shortening (the “wringing” motion). GLS measures longitudinal shortening (the base-to-apex shortening). In HFpEF, subendocardial fibers (which run longitudinally) are impaired by fibrosis and microvascular disease, but mid-wall circumferential fibers compensate → EF is preserved while GLS is reduced.
Clinical implication: A patient with EF 55% and GLS −15% has subclinical systolic dysfunction. GLS is part of the HFA-PEFF algorithm (minor criterion). It predicts outcomes in HFpEF independently of EF.
Pattern: HFpEF GLS is globally reduced (all segments mildly impaired). Compare to cardiac amyloid where the pattern is apical sparing (base and mid are severely reduced, apex is preserved).
LAVI: The Diastolic “HbA1c”: Why this analogy works: Just as HbA1c reflects average blood glucose over 3 months, LAVI reflects average filling pressure over weeks to months. A normal LAVI in a patient with borderline E/e′ suggests recent onset or intermittent elevation. A severely elevated LAVI (>48 mL/m²) means the LA has been stretched chronically — the disease has been present for a long time even if only recently diagnosed.
In HFpEF: One of the 4 ASE variables for elevated filling pressures. Also part of H2FPEF and HFA-PEFF scores. Predicts AF, stroke, hospitalization, and death.
TR Velocity & Pulmonary Pressures: What: Peak tricuspid regurgitation velocity on continuous-wave Doppler. Using the simplified Bernoulli equation: RVSP = 4 × (TR Vmax)² + RAP.
In HFpEF: TR vel >2.8 m/s (≈ RVSP >35 mmHg assuming RAP 5) suggests elevated pulmonary pressures — usually post-capillary PH (elevated LA pressure transmitted to pulmonary circulation). The presence and severity of PH in HFpEF is one of the strongest prognostic markers and defines the “PH phenotype” that may benefit from targeted pulmonary vasodilator therapy (an area of active investigation).
Combined pre- and post-capillary PH (CpcPH): Some HFpEF patients develop a reactive (pre-capillary) component on top of the post-capillary PH → very elevated PASP (>50–60 mmHg) with PVR >2 WU. This group has the worst prognosis.

The ASE Algorithm in Practice For a patient with EF ≥50% and suspected HFpEF, assess 4 variables: (1) Average E/e′ >14, (2) Septal e′ <7 or lateral e′ <10, (3) LAVI >34 mL/m², (4) TR vel >2.8 m/s. If ≥3 of 4 are abnormal → diastolic dysfunction with elevated filling pressures (Grade II). If 2 of 4 → indeterminate (consider exercise echo). If ≤1 → normal filling pressures. Don’t forget: this algorithm applies when the E/A ratio is 0.8–2.0 (the “indeterminate” zone). If E/A <0.8 and E ≤50 cm/s: Grade I (normal pressures). If E/A ≥2.0: Grade III (severely elevated pressures, no further variables needed).

Stage 4 · Phenotyping

HFpEF Is Not One Disease

HFpEF is a heterogeneous syndrome with distinct phenotypes that respond to different therapies. Identifying the dominant phenotype guides management.

Click to expand ↓

Obesity-HFpEF: Most common phenotype. BMI >35, insulin resistance, elevated plasma volume, epicardial fat. Responds to weight loss (STEP-HFpEF: semaglutide improved symptoms, 6MWT, and reduced CRP), diuretics, SGLT2i
Aging/HTN-HFpEF: Older, long-standing HTN, concentric LVH, arterial stiffness. Responds to aggressive BP control, RAAS inhibition (some benefit), SGLT2i, MRA
AF-HFpEF: AF present in 50–70% of HFpEF. AF and HFpEF are bidirectional: LA myopathy drives both. Rate/rhythm control, anticoagulation, and catheter ablation (CASTLE-AF benefit extrapolated) may improve outcomes
PH-HFpEF (CpcPH): Combined pre- and post-capillary PH: PCWP >15 + PVR ≥3 WU. Pulmonary vasodilators NOT helpful (MELODY-1 negative). Treat LV filling pressures. Only diuretics and SGLT2i have evidence
CAD-HFpEF: Ischemic contribution to diastolic dysfunction. REVIVED-BCIS2 (HFrEF) was neutral for PCI; no dedicated HFpEF revascularization trial. Treat as per stable CAD guidelines
Amyloid-HFpEF: See Cardiac Amyloid journey. Screen with GLS apical sparing pattern + ECG low voltage. Tc-PYP scan for ATTR. Tafamidis for ATTR-CM

Stage 5 · Treatment

Guideline-Directed Therapy for HFpEF

Unlike HFrEF, there are fewer mortality-reducing therapies. SGLT2 inhibitors are the breakthrough. Management focuses on decongestion, comorbidity treatment, and phenotype-specific interventions.

Click to expand ↓

AHA/ACC 2022 + ESC 2023 · Pharmacotherapy SGLT2 inhibitors: Empagliflozin (EMPEROR-Preserved) or dapagliflozin (DELIVER). Both showed ~20% reduction in CV death + HF hospitalization. Benefits span EF 40–70%+ and are consistent regardless of diabetes, sex, or age. CLASS I (ESC 2023); CLASS IIa (AHA 2022, published before DELIVER)

Diuretics: Loop diuretics for volume management. CLASS I for congestion

MRA (spironolactone): TOPCAT: US sites showed benefit (HR 0.82 for CV death + HF hosp); Russian sites drove overall neutral result (likely enrollment issues). AHA/ACC: CLASS IIb. Many experts use it routinely for congestion/K management

ARB/ARNI: PARAGON-HF (sacubitril/valsartan): borderline negative overall but EF <57% subgroup and women benefited. CLASS IIb (may be reasonable, especially EF 41–57%)

GLP-1 RA (semaglutide): STEP-HFpEF: semaglutide 2.4 mg/week improved KCCQ by 7.8 points and 6MWT by 20 m in obese HFpEF. STEP-HFpEF DM also positive. Not yet Class I but will likely be incorporated in next guideline updates

BP management: Target <130/80 mmHg (SPRINT). Uncontrolled HTN is the #1 driver of HFpEF. RAAS inhibitors, CCBs (amlodipine), thiazides all reasonable. Avoid verapamil/diltiazem if EF borderline
AF management: Rate control (target <110 bpm initially, <80 if symptomatic). Rhythm control with ablation increasingly favored (EAST-AFNET 4: early rhythm control reduces CV events). Anticoagulation per CHA2DS2-VASc
Exercise training: Cardiac rehabilitation improves exercise capacity and quality of life. Ex-DHF: 3 months supervised training improved peak VO2, E/e', and diastolic function. CLASS I
Weight loss: If BMI >30: target ≥5–10% weight loss. Semaglutide (STEP-HFpEF), bariatric surgery in selected patients. Improves hemodynamics, filling pressures, and symptoms
Iron deficiency: IV iron replacement if deficient (same criteria as HFrEF). Smaller evidence base but pathophysiologically reasonable. CLASS IIb

Stage 6 · Monitoring & Acute Management

Surveillance & Hospitalized HFpEF

HFpEF has a 5-year mortality of 25–35%, similar to HFrEF. Hospitalizations are often for volume overload and are managed similarly to HFrEF decompensation, with emphasis on trigger identification.

Click to expand ↓

Acute management: IV diuretics for decongestion (same approach as HFrEF). Identify trigger: AF with RVR, uncontrolled HTN, dietary indiscretion, medication non-compliance, infection, anemia, renal dysfunction. Address trigger aggressively
Monitoring: Serial echo every 1–2 years (watch for EF decline → transition to HFmrEF/HFrEF). Natriuretic peptides q6–12mo. Annual iron studies. AF surveillance (implantable loop recorder if paroxysmal AF suspected). Monitor for amyloid red flags (progressive LVH, low voltage ECG, carpal tunnel)
Prognosis: Annual mortality 5–8%. Higher in: older age, male, diabetes, AF, LAVI >48, TR vel >3.4, reduced GLS, high NT-proBNP. HFpEF patients die more from non-CV causes (cancer, sepsis, renal failure) than HFrEF patients
Unmet needs: No mortality-reducing therapy proven beyond SGLT2i. Atrial shunt devices (REDUCE LAP-HF II: negative) and LA pacing approaches under investigation. Better phenotyping and precision medicine are the future

Stage 1 · Identification

The Gray Zone: EF 41–49%

HFmrEF (previously HFpEF borderline or HFrEF borderline) is a transitional phenotype. It may represent early HFrEF, recovering HFrEF, or progressive HFpEF. The trajectory matters more than the snapshot.

Click to expand ↓

Definition: EF 41–49% with symptoms/signs of HF. The 2021 ESC universal definition formalized this category. Previous AHA classifications grouped it variably with HFpEF or HFrEF
EF measurement variability: Biplane Simpson: ±5–10% interobserver variability. A measured EF of 45% could be anywhere from 35–55%. Consider 3D echo or CMR for more accurate quantification. Repeat measurements crucial
Subpopulations: Declining from HFpEF: Progressive disease, often ischemic. Worse prognosis. Improving from HFrEF: Responding to GDMT, best prognosis (HFimpEF). Stable HFmrEF: Chronic borderline function, intermediate prognosis
Etiology workup: Same as HFrEF: coronary evaluation (CAD in ~50%), CMR for tissue characterization. Higher proportion of ischemic etiology than HFpEF. Screen for amyloid if LVH present

Stage 2 · Pathophysiology & Echo

The Borderline Heart: Why EF 41–49% Is a Moving Target

HFmrEF is not a fixed phenotype — it is a dynamic state. The echo findings reflect a heart in transition, and understanding the pathophysiology determines whether this patient is early HFrEF, recovering HFrEF, or advanced HFpEF crossing over.

Click to expand pathophysiology ↓

Core Concept · The Transitional Phenotype HFmrEF sits at the intersection of two remodeling patterns. When ischemic: myocyte loss is incomplete → some segments are hypokinetic/akinetic (scar) while others compensate → EF is borderline. When hypertensive HFpEF progresses: chronic pressure overload exhausts compensatory concentric hypertrophy → fibrosis-driven systolic decline. The direction of EF change (improving vs. declining) is more prognostic than the absolute number.

Pathophysiology: Three Populations: 1. Declining from normal/HFpEF (“on the way down”): Progressive fibrosis and myocyte dysfunction. Often ischemic (CAD with incomplete revascularization or chronic ischemia). LV gradually dilates, EF drifts from 55% to 45%. Echo: regional wall motion abnormalities, mild LV dilation, worsening GLS. Worst prognosis in the HFmrEF group.

2. Improving from HFrEF (“on the way up” = HFimpEF): Response to GDMT with reverse remodeling. EF improves from 30% to 45%. LV dimensions may normalize. Echo: improving GLS, resolving MR, decreasing LAVI. Best prognosis. Critical teaching point: DO NOT stop GDMT in HFimpEF. The TRED-HF trial showed that medication withdrawal leads to relapse in >40% within 6 months.

3. Stable HFmrEF (“parked in the middle”): Chronic borderline function, often non-ischemic. May have mixed features of both HFrEF and HFpEF pathophysiology (some dilation + some diastolic dysfunction). Intermediate prognosis.
EF Measurement: The Elephant in the Room: Biplane Simpson EF has ±5–10% inter-observer variability. A measured EF of 45% has a 95% confidence interval of roughly 35–55%. This means an HFmrEF patient could actually have HFrEF or HFpEF depending on who measures. Clinical implications: (1) Never base a major decision on a single EF; (2) 3D echo (±4%) and CMR (±3%) are more reproducible; (3) Serial measurements by the same sonographer on the same machine are most valuable for tracking trajectory.
📊 Echo Deep Dive
GLS: The Trajectory Predictor: In HFmrEF, GLS is more valuable than EF. A patient with EF 45% and GLS −14% is very different from a patient with EF 45% and GLS −18%. The former has more subclinical dysfunction and is more likely to decline to HFrEF; the latter is closer to normal and more likely to improve or stabilize.
Serial GLS tracking: Improving GLS on GDMT predicts EF recovery (HFimpEF trajectory). Worsening GLS despite therapy predicts decline to HFrEF. GLS changes precede EF changes by months — it is the leading indicator.
E/e′ in HFmrEF: Often elevated (>14), reflecting diastolic dysfunction that coexists with mild systolic impairment. In HFmrEF, both systolic AND diastolic dysfunction are present — this is part of what makes the phenotype intermediate. Filling pressure elevation (E/e′ >14) is present in most HFmrEF patients and correlates with symptoms and hospitalizations. Decreasing E/e′ on therapy is a positive prognostic sign.
Diastolic Function Assessment: Apply the same ASE algorithm as for reduced EF: E/A, E/e′, LAVI, TR velocity. Most HFmrEF patients have Grade I or II diastolic dysfunction. Grade III (restrictive) in HFmrEF suggests worse prognosis and likely progression to HFrEF.
Key distinction from HFpEF: In HFpEF, diastolic dysfunction is the primary problem. In HFmrEF, both systolic and diastolic dysfunction contribute. The balance between the two helps determine whether the patient is “more like HFrEF” or “more like HFpEF.”
RV Function in HFmrEF: Often overlooked. TAPSE <17 mm or S′ <9.5 cm/s in the setting of EF 41–49% suggests biventricular involvement and significantly worsens prognosis. RV free wall strain may detect subclinical RV dysfunction even when TAPSE is borderline normal.
Clinical pearl: If RV function is preserved and EF is improving on serial echo, this patient has an excellent prognosis (HFimpEF trajectory). If RV function is declining alongside borderline LV function, this patient needs aggressive optimization and close follow-up.
Wall Motion Analysis: Regional wall motion abnormalities (WMAs) in HFmrEF strongly suggest ischemic etiology. Global hypokinesis without WMAs suggests non-ischemic (DCM, toxic, metabolic). This distinction matters because: ischemic HFmrEF may benefit from revascularization (STICH trial subgroups showed most benefit in EF 35–50%), while non-ischemic HFmrEF has better response to GDMT with higher rates of EF recovery.

The Bottom Line for HFmrEF Echo The most important echo parameter in HFmrEF is the trajectory. Order repeat echo at 3–6 months on optimized GDMT. Track: EF, GLS, LV dimensions, LAVI, and RV function. Is the patient getting better, staying the same, or getting worse? The answer determines classification (HFimpEF vs. stable vs. progressive) and guides device therapy eligibility (ICD only if EF ≤35%), transplant evaluation, and prognosis counseling.

Stage 3 · Treatment

Guideline-Directed Therapy

Most HFrEF therapies show benefit in subgroup analyses of HFmrEF patients. Guidelines increasingly recommend treating HFmrEF like HFrEF.

Click to expand ↓

AHA/ACC 2022 SGLT2 inhibitors: CLASS IIa for HFmrEF (DELIVER included EF 41–49%)
ARNI/ACEi/ARB: CLASS IIb (PARAGON-HF subgroup EF <57% showed benefit)
MRA: CLASS IIb (TOPCAT subgroup analysis)
Beta-blockers: CLASS IIb (meta-analyses suggest mortality benefit in EF <50%)
Diuretics: CLASS I for congestion

ESC 2023 Focused Update ESC gives stronger recommendations for HFmrEF treatment than AHA/ACC: SGLT2i are CLASS I, and ACEi/ARB/ARNI, BB, MRA are all CLASS IIa. The 2023 update explicitly states "consider treatments used in HFrEF." In practice, most HF specialists treat HFmrEF with full HFrEF quadruple therapy.

Practical approach: Treat with all four HFrEF pillars (ARNI/ACEi, BB, MRA, SGLT2i). The evidence is not as robust as HFrEF but the risk-benefit ratio favors treatment, especially as EF measurement has significant variability (±5–10%)
ICD/CRT: Current guidelines require EF ≤35% for primary prevention ICD. HFmrEF patients (41–49%) do not qualify. However, if EF declines to ≤35% on repeat echo, device evaluation is indicated. CRT: same QRS/LBBB criteria apply
Monitor for trajectory: Repeat echo at 3–6 months. If improving toward >50%: HFimpEF (excellent prognosis, continue GDMT). If declining toward ≤40%: transition to HFrEF management (ICD evaluation, advanced HF referral if appropriate)

Stage 4 · Outcomes

Trajectory & Reclassification

The key in HFmrEF is serial assessment. ~40% will improve (HFimpEF), ~30% remain stable, ~30% decline to HFrEF. Prognosis is intermediate between HFrEF and HFpEF.

Click to expand ↓

EF trajectory: Improving EF (HFimpEF): best prognosis, 2–5% annual mortality. Stable HFmrEF: intermediate, 5–8%. Declining to HFrEF: worst, 10–15% annual mortality. Direction of EF change is more prognostic than absolute EF number
GLS role: GLS may better stratify risk than EF in the 41–49% range. GLS <-12% carries HFrEF-like prognosis regardless of EF. GLS improves earlier than EF with GDMT — useful for monitoring treatment response
When to reassess: Repeat echo 3–6 months after GDMT optimization, then annually. If reclassified as HFrEF (≤40%): full HFrEF pathway including device evaluation. If improved (>50%): continue all GDMT, reclassify as HFimpEF

Stage 1 · Recognition

Identifying Right Heart Failure

RV failure presents with systemic venous congestion: JVD, peripheral edema, hepatomegaly, ascites. Dyspnea may be less prominent than in LV failure. The first step is determining whether RV failure is primary or secondary to left heart disease.

Click to expand ↓

Signs of RV failure: JVD (most sensitive), hepatojugular reflux, peripheral edema, ascites, pulsatile liver (severe TR), Kussmaul sign (JVP rises with inspiration = RV non-compliance), RV heave, loud P2 (PH), holosystolic murmur at LLSB (TR, increases with inspiration = Carvallo sign)
Key distinction: Acute: Thin-walled dilated RV (hasn't had time to hypertrophy). PE, RV infarct, acute myocarditis. Chronic: Thick-walled dilated RV (hypertrophy from sustained pressure overload). PH, left heart disease, chronic lung disease
Echo essentials: RV size (basal diameter, RV/LV ratio), RV wall thickness (>5 mm = chronic), TAPSE, S', FAC, RV free wall strain, TR severity, IVC/RAP, RVSP, septum shape (D-sign), and LV filling pressures (to distinguish Group 2 PH from pre-capillary PH)

Stage 2 · Etiology & PH Classification

Why Is the RV Failing?

The WHO classification of pulmonary hypertension drives treatment. Group 2 (left heart disease) is the most common cause. Treatment differs dramatically by group.

Click to expand ↓

Group 1: PAH: Pulmonary arterial hypertension. Pre-capillary: mPAP >20, PCWP ≤15, PVR >2 WU. Idiopathic, heritable (BMPR2), drug-induced, CTD-associated (scleroderma), HIV, portopulmonary. Treated with pulmonary vasodilators (ERA, PDE5i, prostacyclins, riociguat)
Group 2: Left heart disease: Most common PH. Post-capillary: PCWP >15. Isolated post-capillary (IpcPH): PVR <2 WU. Combined pre+post (CpcPH): PVR ≥2 WU. Treat underlying LHD. Pulmonary vasodilators are NOT indicated (and may cause harm by flooding a non-compliant LA)
Group 3: Lung disease: COPD, ILD, OSA, chronic hypoxia. Treat underlying lung disease, supplemental O2. Pulmonary vasodilators generally not recommended (worsen V/Q mismatch) except in severe PH-ILD where inhaled treprostinil (INCREASE trial) showed benefit
Group 4: CTEPH: Chronic thromboembolic PH. V/Q scan is screening test of choice (high sensitivity). Treatment: pulmonary endarterectomy (PEA) is potentially curative. If inoperable: balloon pulmonary angioplasty (BPA) or riociguat (CHEST-1 trial)
Group 5: Multifactorial: Sarcoidosis, hematologic disorders, metabolic diseases, systemic disorders. Treat underlying condition
Right heart catheterization: Required for definitive PH diagnosis and classification. Measures: RA, RV, PA (systolic/diastolic/mean), PCWP, CO (thermodilution or Fick), PVR, TPG, DPG. Vasoreactivity testing (inhaled NO) for Group 1 PAH to identify CCB responders

2022 ESC/ERS PH Guidelines New hemodynamic definition: mPAP >20 mmHg (lowered from >25). Pre-capillary PH: mPAP >20 + PCWP ≤15 + PVR >2 WU. Post-capillary PH: mPAP >20 + PCWP >15. Combined: PCWP >15 + PVR >2 WU. Exercise PH: mPAP/CO slope >3 mmHg/L/min (new concept).

Stage 3 · Pathophysiology & Echo

The Forgotten Ventricle: RV Mechanics & Why It Fails Differently

The RV is fundamentally different from the LV in structure, function, and failure mechanisms. Understanding RV physiology explains why echo parameters differ, why the RV tolerates volume better than pressure, and why RV failure is the terminal event in most forms of heart failure.

Click to expand pathophysiology ↓

Core Concept · RV vs. LV: Built for Different Jobs The LV is a thick-walled pressure pump that generates systemic pressures (∼120 mmHg systolic). The RV is a thin-walled (∼3–5 mm) volume pump that pushes blood through the low-resistance pulmonary circuit (∼25 mmHg systolic). The RV does 1/5 the stroke work of the LV. Its crescent shape wraps around the LV, and it contracts primarily by longitudinal shortening (base-to-apex) and free wall inward motion. This is why TAPSE (longitudinal excursion) is so informative for RV function.

RV Contraction Mechanics: Three mechanisms: (1) Longitudinal shortening (tricuspid annulus moves toward apex) — this is what TAPSE and S′ measure; (2) Free wall inward motion — this is what FAC captures; (3) Interventricular septal contribution — the LV contraction pulls the septum toward the LV, assisting RV ejection. This “ventricular interdependence” means that LV failure reduces RV contractile assistance — one reason RV failure follows LV failure.

No single parameter captures the whole picture because of the complex geometry. The ASE recommends reporting at least two RV systolic parameters.
Pressure vs. Volume Overload: Volume overload (ASD, TR, pulmonary regurgitation): RV dilates. Wall thickness stays normal or mildly increased. RV tolerates volume overload reasonably well for years because the thin wall is compliant. Echo: dilated RV, preserved TAPSE initially, reduced FAC.

Pressure overload (PH, pulmonic stenosis): RV hypertrophies (wall >5 mm). Initially maintains output. But the RV wall has limited hypertrophic capacity — eventually decompensates with dilation. The transition from “compensated RV hypertrophy” to “decompensated RV dilation” is the critical point. Echo: RV hypertrophy → RV dilation + reduced TAPSE/S′ = RV failure.

Acute RV failure (massive PE, RV infarct): Thin-walled RV cannot acutely generate pressures above ∼60 mmHg. Acute obstruction (PE) or contractile loss (infarct) → acute dilation, cardiogenic shock. Echo: acutely dilated thin-walled RV, McConnell sign, TAPSE <17.
RV Coronary Perfusion: The Unique Vulnerability: The RV is perfused in both systole and diastole (unlike the LV which is primarily diastole). In RV hypertension, RV systolic pressure approaches aortic pressure → systolic perfusion diminishes → RV ischemia even without coronary disease. This creates a vicious cycle: RV HTN → RV ischemia → RV dysfunction → reduced CO → reduced aortic pressure → further reduction in RV perfusion gradient. This is why RV failure in PH can decompensate rapidly and catastrophically.
Ventricular Interdependence: The RV and LV share the interventricular septum, a pericardial sac, and coronary supply. When the RV dilates: (1) Septum bows toward LV (D-shaped LV on PSAX) → impairs LV filling → reduces LV output; (2) Pericardial constraint means total cardiac volume is relatively fixed → RV dilation compresses LV; (3) Reduced LV preload from poor RV output. This is why advanced RV failure causes systemic hypotension and cardiogenic shock even with preserved LV contractility.

Attending-Level Concept The most critical clinical decision in RV failure is distinguishing Group 2 PH (left heart disease) from pre-capillary PH (Groups 1, 3, 4). In Group 2: treat the left heart (diuresis, GDMT, MV intervention). Pulmonary vasodilators are CONTRAINDICATED (may flood a non-compliant LA with blood, worsening pulmonary edema). In pre-capillary PH: pulmonary vasodilators are the primary therapy. Getting this wrong can be fatal. The key discriminator is the PCWP on right heart catheterization (≤15 = pre-capillary; >15 = post-capillary).

📊 Echo Deep Dive
TAPSE (Tricuspid Annular Plane Systolic Excursion): What: M-mode cursor placed on the lateral tricuspid annulus in A4C view. Measures the distance the annulus moves toward the apex during systole.
What it reflects: RV longitudinal shortening — the dominant RV contractile mechanism.
Normal: ≥17 mm. <17 mm = RV systolic dysfunction.
Strengths: Simple, reproducible, widely available. Takes 10 seconds to measure.
Limitations: (1) Angle-dependent (only measures longitudinal motion in one plane); (2) Load-dependent (afterload reduction can improve TAPSE without true contractility change); (3) After cardiac surgery, TAPSE drops due to pericardial adhesions even with preserved RV function; (4) Does not capture free wall inward motion or septal contribution.
S′ (RV Tissue Doppler): What: Peak systolic velocity of the lateral tricuspid annulus by pulsed-wave tissue Doppler.
Normal: ≥9.5 cm/s. <9.5 = RV dysfunction.
Complements TAPSE: Both measure longitudinal function but by different methods. If both are abnormal, RV dysfunction is confirmed. If discordant, consider alternative measures (FAC, strain).
FAC (Fractional Area Change): What: (End-diastolic area − end-systolic area) / end-diastolic area × 100. Traced in A4C view.
Normal: ≥35%. <35% = RV dysfunction.
Advantage over TAPSE: Captures both longitudinal AND radial (free wall inward) motion. Correlates best with RV EF by CMR. Less affected by post-surgical changes.
Limitation: Requires careful endocardial tracing (heavily trabeculated RV makes this challenging). Higher inter-observer variability than TAPSE.
RV Free Wall Strain: What: Speckle-tracking longitudinal strain of the RV free wall (3 segments: basal, mid, apical). Average of the three.
Normal: More negative than −20% (i.e., −22%, −25% are normal).
Why it matters: Less load-dependent than TAPSE or S′. Detects subclinical RV dysfunction. May be the earliest echo marker of RV decompensation in PH.
In PH: Progressive worsening of RV strain correlates with clinical deterioration. Strain > −15% (less negative) predicts poor outcomes.
IVC & RAP Estimation: Algorithm: IVC diameter (≤2.1 cm vs. >2.1 cm) + sniff collapse (>50% vs. <50%) = RAP estimate (3, 8, or 15 mmHg). Critical for calculating RVSP = 4(TRVmax)² + RAP.
In RV failure: Plethoric IVC (>2.1 cm, <50% collapse) = RAP ≥15 mmHg. This finding indicates significant right heart congestion and is a red flag for impending clinical decompensation. A dilated, non-collapsing IVC in the setting of low TAPSE and elevated TR velocity paints a clear picture of advanced RV failure.
D-Sign (Septal Configuration): What: On parasternal short-axis view, the interventricular septum bows toward the LV, making the LV appear “D-shaped” instead of circular.
Timing determines etiology: D-sign in systole only = RV pressure overload. D-sign in diastole only = RV volume overload. D-sign in both = combined pressure + volume overload (most severe).
Clinical significance: D-sign with hemodynamic compromise suggests RV failure is contributing to systemic hypotension through ventricular interdependence (RV compresses LV → reduced LV filling → low CO).

The McConnell Sign — Know It, Don’t Over-rely on It RV free wall akinesia with preserved apical contractility. Classically described in acute PE (sensitivity 77%, specificity 94%). However, it can also be seen in RV infarct and is NOT 100% specific. The “60/60 sign” (RVSP <60 mmHg + PA acceleration time <60 ms) combined with McConnell is more specific for acute PE. In chronic PH, the entire RV is hypokinetic (no apical sparing) — this helps distinguish acute from chronic.

Stage 4 · Treatment

Managing the Failing Right Heart

Treatment strategy depends entirely on etiology. For Group 2 PH: treat LHD. For Group 1 PAH: combination pulmonary vasodilator therapy. For acute RV failure: hemodynamic support and cause-specific treatment.

Click to expand ↓

General RV failure Rx: Diuretics for congestion (RV is preload-sensitive — avoid over-diuresis). Maintain sinus rhythm (RV depends on atrial kick more than LV). Optimize RV preload, reduce RV afterload, support RV contractility. Avoid hypoxia and acidosis (worsen PVR)
Acute RV failure: Volume: cautious — RV Frank-Starling curve is steep. Avoid aggressive fluids (overdistension worsens septal bowing and LV filling). If hypotensive: vasopressors (norepinephrine preferred). Inotropes: milrinone (pulmonary vasodilation + inotropy) or dobutamine. Inhaled NO or epoprostenol for selective pulmonary vasodilation
Acute PE with RV strain: Anticoagulation (heparin). Systemic thrombolysis (alteplase) if massive PE (hemodynamic instability). Catheter-directed therapy (EKOS, FlowTriever) for submassive PE with RV dysfunction. Surgical embolectomy for failed thrombolysis or contraindication
Group 1 PAH therapy: ERA (ambrisentan, macitentan) + PDE5i (sildenafil, tadalafil) or riociguat. Upfront combination therapy is standard (AMBITION trial). Prostacyclin pathway: IV epoprostenol, SC/IV treprostinil, inhaled iloprost, oral selexipag. Sotatercept (activin signaling inhibitor, STELLAR trial) is a breakthrough add-on therapy
Functional TR: Tricuspid valve intervention for severe symptomatic TR refractory to medical therapy. TRILUMINATE Pivotal (TriClip TEER): improved quality of life. Surgical repair at time of left-sided valve surgery if moderate+ TR

Critical Concept Ventricular interdependence: The RV and LV share the interventricular septum and pericardial space. RV dilation pushes the septum leftward (D-shaped LV), impairing LV filling and reducing CO — creating a death spiral. Breaking this cycle (reduce RV afterload, support contractility, cautious diuresis) is the therapeutic goal.

Stage 5 · Advanced & Prognosis

Advanced RV Failure & Outcomes

Refractory RV failure carries very high mortality. Options include mechanical support (RVAD), lung transplant (Group 1 PAH), or heart-lung transplant.

Click to expand ↓

Prognostic markers: RA pressure >15 mmHg, CI <2.0, rising BNP, renal dysfunction, hepatic congestion (elevated INR, bilirubin), hyponatremia. Echo: TAPSE <10 mm, RV FAC <25%, free wall strain >-13%
Mechanical support: RVAD (Impella RP, ProTek Duo, surgically-implanted) for acute refractory RV failure. Bridge to recovery or transplant. No durable RVAD commercially available for destination therapy
Transplant: Bilateral lung transplant for Group 1 PAH (if RV expected to recover post-transplant). Heart-lung transplant for irreversible biventricular failure. Heart transplant with PVR <5 WU (must be responsive to vasodilator challenge)
RV failure post-LVAD: Occurs in 20–40% of LVAD implants. Risk factors: high RA/PCWP ratio, low RVSWI, severe TR, hepatic dysfunction. Temporary RVAD needed in 5–10%. Predicting RV failure pre-LVAD is one of the hardest problems in advanced HF

Stage 1 · Red Flags

When to Suspect Cardiac Amyloidosis

Cardiac amyloidosis is vastly underdiagnosed. ATTR-CM may affect up to 13% of elderly patients with HFpEF. Recognition of "red flag" combinations is the key to early diagnosis.

Click to expand ↓

Echo red flags: LV wall thickness ≥12 mm without history of HTN; biventricular thickening; granular sparkling myocardium; biatrial dilation with small/normal ventricles; thickened interatrial septum; mild valve thickening; small pericardial effusion; GLS with apical sparing pattern
ECG red flags: Low voltage or pseudo-infarct pattern (Q waves without CAD) DESPITE thick walls on echo. This ECG-echo discordance (thick walls + low voltage) is virtually pathognomonic. Also: AV block, bundle branch block (conduction disease disproportionate to other cardiac disease)
Clinical red flags: Bilateral carpal tunnel syndrome (especially if preceding HF by years), lumbar spinal stenosis, biceps tendon rupture, peripheral neuropathy (ATTR variant), autonomic neuropathy (orthostatic hypotension), unexplained nephrotic syndrome (AL), macroglossia (AL), periorbital purpura (AL, pathognomonic), intolerance to ACEi/BB (fixed SV)
Red flag combinations: High suspicion: HFpEF + LVH + low voltage ECG. HFpEF + bilateral carpal tunnel. HFpEF + LVH + aortic stenosis (13–16% of severe AS patients have occult ATTR). HFpEF + LVH + peripheral neuropathy

Key Teaching Point Think of cardiac amyloid in every patient with HFpEF and unexplained LVH. The prevalence of ATTR-CM in HFpEF is much higher than previously thought (up to 13% in autopsy studies). With tafamidis available, early diagnosis directly improves survival. The cost of missing it is high.

Stage 2 · Diagnostic Pathway

AL vs. ATTR: The Critical Distinction

The diagnostic algorithm MUST first exclude AL amyloidosis (plasma cell dyscrasia) because it requires urgent chemotherapy. Only after AL is excluded can ATTR be diagnosed non-invasively with nuclear scintigraphy.

Click to expand ↓

Diagnostic Algorithm (ASC/ISA Consensus) Step 1: Suspect cardiac amyloidosis based on red flags.
Step 2: Exclude AL amyloidosis: serum free light chains (kappa/lambda ratio), SPEP/UPEP with immunofixation. If ANY abnormality → hematology referral + tissue biopsy (fat pad, bone marrow, or endomyocardial).
Step 3: If light chains NORMAL → Tc-PYP (US) or Tc-DPD/Tc-HMDP (Europe) nuclear scintigraphy.
Step 4: Grade 2–3 cardiac uptake + negative light chains = ATTR-CM diagnosis WITHOUT biopsy. Grade 0–1 = consider other diagnoses or biopsy if clinical suspicion remains high.

Serum free light chains: Kappa/lambda ratio: normal 0.26–1.65. Abnormal ratio with elevated involved light chain suggests AL. Sensitivity >95% when combined with SPEP/UPEP/immunofixation. FALSE POSITIVES: renal dysfunction raises both chains (ratio may remain normal)
Tc-99m PYP scan (US): Pyrophosphate scan. Grade 0: no uptake. Grade 1: less than bone. Grade 2: equal to bone. Grade 3: greater than bone. Grade 2–3 with negative light chains = ATTR-CM (sensitivity 99%, specificity >85%). Must do SPECT to exclude blood pool artifact (false positive)
Cardiac MRI: Diffuse subendocardial or transmural LGE. Characteristic difficulty nulling myocardium (amyloid changes gadolinium kinetics). Elevated native T1, elevated ECV (>0.45 highly suggestive). Supportive but cannot distinguish AL from ATTR
Endomyocardial biopsy: Gold standard for typing. Required if: (1) AL suspected (light chains abnormal); (2) PYP equivocal (Grade 1); (3) Both light chains abnormal AND PYP positive (could be dual pathology). Congo red staining → apple-green birefringence. Mass spectrometry for definitive subtyping
Genetic testing: All ATTR patients should undergo TTR gene sequencing: wild-type ATTR (ATTRwt, formerly senile) vs. hereditary/variant ATTR (ATTRv). V122I most common in African Americans (3–4% carrier frequency). T60A, V30M are other common variants. Genetic counseling for family screening

Stage 3 · Pathophysiology & Echo

Amyloid Infiltration: Why the Heart Gets Stiff, Sparkly, and Electrically Silent

Cardiac amyloidosis is the archetypal infiltrative cardiomyopathy. Misfolded protein deposits in the extracellular space between myocytes, progressively increasing wall thickness while destroying normal tissue architecture. Every echo finding has a direct pathologic correlate — understanding the mechanism transforms the echo from a static image into a molecular story.

Click to expand pathophysiology ↓

Core Concept · Two Diseases, One Heart AL amyloidosis: Plasma cell dyscrasia produces misfolded immunoglobulin light chains. These are directly cardiotoxic — they cause myocyte damage PLUS extracellular deposition. Rapid progression (months). Untreated median survival: 6 months with cardiac involvement. URGENT: requires immediate hematology referral for chemotherapy.

ATTR amyloidosis: Transthyretin (TTR, a hepatic protein that transports thyroxine and retinol) misfolds and aggregates. Two types: wild-type (ATTRwt, previously “senile cardiac amyloidosis,” age-related destabilization of normal TTR, predominantly men >65) and hereditary (ATTRv, TTR gene mutations, most common: V122I in 3–4% of African Americans, T60A, V30M). Slower progression (years). TTR stabilizers (tafamidis) improve survival.

Molecular Pathology: Deposition pattern: Amyloid fibrils deposit in the extracellular interstitial space, between and around myocytes. They form rigid beta-pleated sheets that stiffen the myocardium and disrupt cell-to-cell electrical coupling. The amyloid wraps around myocytes like casting a limb in plaster.

Why walls thicken: Amyloid protein accumulates between myocytes, physically expanding the interstitium → increased wall thickness. This is NOT hypertrophy (myocytes are not larger) — it is infiltration. The wall gets thicker, but the muscle gets weaker. This is the opposite of hypertensive LVH where walls thicken from myocyte growth.

Why ECG voltage drops: Amyloid is electrically inert. It dilutes the electrical signal from myocytes. As more amyloid accumulates, the QRS voltage drops. The classic ECG-echo discordance: thick walls on echo (looks like LVH) + low voltage on ECG (looks like no LVH) = virtually pathognomonic for amyloid. No other common condition produces this pattern.
Hemodynamic Consequences: Restrictive physiology: Amyloid infiltration destroys LV compliance. The ventricle cannot stretch to accept blood → filling pressures rise dramatically. E/A >2.0, DT <150 ms. This is Grade III diastolic dysfunction — the most severe pattern.

Fixed stroke volume: Because the stiff ventricle has a fixed end-diastolic volume, stroke volume cannot increase with demand. Patients are profoundly exercise-intolerant. Heart rate is the only mechanism to increase CO — but these patients often have conduction disease limiting chronotropic response.

Why standard HF drugs are poorly tolerated: ACEi/ARBs cause hypotension (fixed SV + vasodilation = dangerously low BP). Beta-blockers reduce the only compensatory mechanism (HR). Digoxin binds to amyloid fibrils → toxic accumulation. Volume management (careful diuresis) is the mainstay of supportive care.

Attending-Level Concept The key to the GLS apical sparing pattern lies in the deposition gradient. Amyloid deposits preferentially in the basal and mid-segments (higher wall stress, more interstitial space from thicker walls). The apex has the least deposition. Therefore: basal and mid-wall GLS are severely impaired (>−5%), while apical GLS may be relatively preserved (−15% to −20%). This creates the pathognomonic “cherry on top” or “bullseye” pattern on the strain polar map. No other condition reliably produces this pattern — it has >90% sensitivity and specificity for cardiac amyloidosis.

📊 Echo Deep Dive
Wall Thickness: Infiltration, Not Hypertrophy: IVSd and LVPWd: Typically ≥12–15 mm in ATTR, may be slightly less in AL (shorter disease duration). Biventricular thickening is characteristic — RV free wall also thickens (>5 mm), which does NOT occur in hypertensive LVH or HCM.
Interatrial septum thickening (>6 mm): Amyloid deposits in the atrial septum. This finding is unusual in other causes of LVH and should raise suspicion.
Valve thickening: Mild, non-hemodynamically significant thickening of mitral and aortic leaflets. Amyloid deposits on valve tissue — another finding not seen in HTN/HCM.
Granular sparkling: Classic teaching but actually has low sensitivity (∼30%) with modern harmonic imaging. Don’t rely on it. Better detected with older fundamental imaging settings.
GLS with Apical Sparing: The Pathognomonic Pattern: The pattern: Basal segments GLS >−5% to −8% (severely impaired). Mid segments −8% to −12% (moderately impaired). Apical segments −15% to −25% (relatively preserved).
Why: Amyloid deposition follows a base-to-apex gradient. The base has the most infiltration → worst function. The apex has the least → best function.
Relative apical sparing ratio: (Average apical strain) / (Average basal + mid strain). A ratio >1.0 strongly suggests amyloid. >2.1 is highly specific. Some institutions use >2.9 as the cutoff. This is a better discriminator than absolute GLS values.
Differential: HFpEF with concentric LVH shows globally reduced GLS WITHOUT apical sparing (all segments equally impaired). Ischemic disease shows regional wall motion abnormalities in coronary territories (not a base-to-apex gradient).
Diastolic Function: Always Abnormal: E/e′: Markedly elevated (>15–20). Often >20 in advanced disease.
E/A: Usually ≥2.0 (restrictive pattern, Grade III). In early disease, may be pseudonormal (Grade II) — always check tissue Doppler.
DT: <150 ms in restrictive physiology. Rapid pressure equalization reflects the profoundly non-compliant LV.
LAVI: Severely dilated (>48 mL/m²) due to chronically elevated filling pressures. Biatrial dilation with normal/small LV cavity = classic amyloid pattern.
LA strain: Severely reduced (<15%). Amyloid infiltrates the atria too, causing atrial mechanical failure (contributes to AF and thromboembolic risk even in sinus rhythm).
RV Assessment in Amyloid: RV wall thickening + RV dysfunction is common and prognostic. TAPSE <14 mm in cardiac amyloidosis carries very poor prognosis. RV involvement distinguishes amyloid from other causes of restrictive cardiomyopathy (radiation, for example, often spares the RV).
Clinical pearl: If the RV wall is >5 mm and the patient doesn’t have PH, think infiltrative disease (amyloid, sarcoid, Fabry).
Pericardial Effusion: Small pericardial effusion is present in ∼40–50% of cardiac amyloidosis. Not hemodynamically significant but adds to the overall pattern. The amyloid deposits in the pericardium itself, causing mild serous fluid accumulation.
Distinguishing AL from ATTR on Echo: AL: Wall thickness often less extreme (<15 mm) because disease duration is shorter. LV function may be more severely impaired relative to wall thickness (direct myocyte toxicity from light chains). More likely to have preserved or mildly reduced EF at presentation. Faster progression on serial echo (weeks to months).
ATTR: Wall thickness often ≥15–18 mm (long duration of deposition). EF may be preserved until late. Slower progression on serial echo (months to years). More conduction disease (first-degree AV block, bundle branch blocks). More likely to have concomitant aortic stenosis (13–16% overlap).

The Amyloid Echo Checklist When amyloid is suspected, systematically evaluate: (1) LV wall thickness (concentric, ≥12 mm without clear HTN history); (2) RV wall thickness (>5 mm = biventricular involvement); (3) Interatrial septal thickness (>6 mm); (4) Valve thickening (non-hemodynamic); (5) GLS with apical sparing (polar map); (6) Diastolic parameters (E/e′, E/A, DT → restrictive pattern); (7) LAVI (severely dilated); (8) Small pericardial effusion; (9) “Granular sparkling” (low sensitivity but still taught). If ≥3 of these features are present in a patient with HFpEF or unexplained LVH, proceed immediately to light chain testing + nuclear scintigraphy.

Stage 4 · Treatment

Disease-Modifying & Supportive Therapy

Treatment differs dramatically between AL (chemotherapy targeting plasma cells) and ATTR (TTR stabilizers/silencers). Supportive HF management has unique considerations due to the stiff ventricle.

Click to expand ↓

ATTR-CM Treatment Tafamidis 80 mg daily (or tafamidis meglumine 20 mg): ATTR-ACT trial: 30% reduction in all-cause mortality, 32% reduction in CV hospitalizations over 30 months in NYHA I–III ATTR-CM. CLASS I (ESC 2023). FDA-approved for ATTR-CM (both wild-type and hereditary).

Emerging ATTR therapies:
• Acoramidis (AG10): more potent TTR stabilizer. ATTRibute-CM trial: met primary endpoint, may be more effective than tafamidis
• Patisiran (RNA interference): APOLLO-B trial positive for ATTR-CM. Silences TTR mRNA production
• Vutrisiran: subcutaneous RNAi. HELIOS-B: 33% reduction in CV death + events
• Eplontersen: antisense oligonucleotide. CARDIO-TTRansform ongoing

AL Amyloidosis Treatment Urgent hematology referral. Chemotherapy targeting clonal plasma cells:
• First-line: CyBorD (cyclophosphamide + bortezomib + dexamethasone) ± daratumumab (ANDROMEDA trial: daratumumab-CyBorD superior to CyBorD alone)
• Autologous stem cell transplant in eligible patients (selected, cardiac stage I–II)
• Response measured by free light chain reduction and cardiac biomarker improvement (NT-proBNP, troponin)
• Median survival without treatment: 6 months for Stage III cardiac AL. With modern therapy: 3–5 years for most stages

HF management caveats: Diuretics: Mainstay for congestion. Often need high doses. Monitor closely — narrow therapeutic window between congestion and hypotension (fixed stroke volume). ACEi/ARB: Poorly tolerated (orthostatic hypotension from autonomic neuropathy + fixed SV). Beta-blockers: Avoid or use extreme caution — patients are HR-dependent for CO (fixed SV means CO = SV × HR; dropping HR drops CO). Digoxin: CONTRAINDICATED — binds to amyloid fibrils, causing toxicity at therapeutic levels. CCBs (verapamil/diltiazem): CONTRAINDICATED — bind amyloid, cause profound hypotension and heart block
SGLT2 inhibitors: Emerging evidence suggests benefit in ATTR-CM. EMPEROR-Preserved included some amyloid patients. Reasonable to use for volume management. Avoid excessive dehydration in setting of fixed SV
Device therapy: Pacemaker: frequently needed for conduction disease (progressive AV block, sinus node dysfunction). ICD: controversial — PEA is the more common mode of death (not VT/VF), so ICD benefit is uncertain. CRT: no evidence in amyloid specifically
Transplant: Heart transplant: possible for AL (after hematologic remission) and ATTR (select cases). For ALwt (senile): age often precludes transplant. Combined heart-liver transplant for ATTR variant (liver produces TTR) — largely supplanted by TTR stabilizers/silencers

Stage 5 · Monitoring & Prognosis

Surveillance & Outcomes

Prognosis depends on subtype, cardiac stage, and treatment response. ATTR-CM with tafamidis: median survival >5 years. AL with cardiac involvement: highly variable, driven by hematologic response.

Click to expand ↓

ATTR staging (Gillmore): Stage I: NT-proBNP ≤3000 + eGFR ≥45. Stage II: one abnormal. Stage III: both abnormal. Median survival: Stage I ~70 mo, II ~47 mo, III ~24 mo (without tafamidis). Tafamidis improves all stages
AL staging (Mayo 2012): Uses NT-proBNP (≥1800 pg/mL), cTnT (≥0.025 ng/mL), dFLC (≥180 mg/L). Stage I: 0 elevated (median OS 94 mo). Stage II: 1 (40 mo). Stage III: 2 (14 mo). Stage IV: all 3 (6 mo). Staging drives treatment intensity and transplant eligibility
Monitoring ATTR: Echo q6–12 mo (wall thickness, EF, GLS, diastolic parameters, TR vel). NT-proBNP q3–6 mo. 6MWT, KCCQ for functional assessment. Repeat PYP scan not routine (doesn't reliably track disease activity)
Monitoring AL: Hematologic response: monthly free light chains during treatment. Cardiac response: NT-proBNP decrease ≥30% or ≥300 pg/mL from baseline = cardiac response. Troponin normalization. Echo improvement lags behind biomarker improvement by months
Family screening (ATTRv): Genetic counseling and cascade testing for first-degree relatives of ATTRv patients. Asymptomatic carriers: annual ECG, echo, NT-proBNP starting ~10 years before expected symptom onset for that variant. Early tafamidis initiation in symptomatic carriers

The Amyloid Revolution Cardiac amyloidosis has transformed from a diagnosis of despair to a treatable condition. Tafamidis was the first disease-modifying therapy (2018); RNAi agents and more potent stabilizers are now available. The bottleneck is diagnosis — awareness and screening are the most important interventions. Every HFpEF patient with unexplained LVH deserves amyloid screening.